Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Lehman Downgrades CancerVax to Neutral


Lehman Brothers downgraded CancerVax (CNVX) to neutral from positive.

Analyst Craig Parker thinks current valuations have discounted the positive attributes of the biotechnology sector. As a result, he downgraded the sector. He notes the sector has achieved a level of financial maturity reflected in product sales of $30 billion-plus, an average operating margin for profitable companies of 34%, and sales growth of 20%-plus.

However, Parker believes with increased reimbursement pressures, intensfied competition in most categories, and anticipated deceleration in sales growth in 2005, the sector could trade at a discount to historic levels for the next 12 months.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus